ATRA

Atara Biotherapeutics, Inc.

Insider Trades

NameValueActionPriceCurrent Price
Nguyen AnhCoDirector, Officer: President And CEO
$48k5.2k shares
SellMay 18, 2026
$9.13
--
Grant-Huerta YaninaChief Accounting Officer
$22k2.4k shares
SellMay 18, 2026
$9.13
--
EcoR1 Capital, LLC10 Percent Owner
$4.7M507.4k shares
BuyMay 7, 2026
$9.35
--
Panacea Innovation Ltd10 Percent Owner
$3.2M313.4k shares
SellMay 7, 2026
$10.10
--
Grant-Huerta YaninaChief Accounting Officer
$1.9k377 shares
SellMar 2, 2026
$5.08
--
Grant-Huerta YaninaChief Accounting Officer
$508100 shares
SellMar 2, 2026
$5.08
--

News

businesswire.comAtara Biotherapeutics Announces Changes to Its Board of Directorsbusinesswire.comJun 12globenewswire.comQuetzal Therapeutics Announces First Patient Dosed in Phase 3 QUATRO-APL Trial of QTX-2101 for Frontline Acute Promyelocytic Leukemiaglobenewswire.comJun 11prnewswire.comThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRAprnewswire.comMay 26gurufocus.comATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rightsgurufocus.comMay 22businesswire.comATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rightsbusinesswire.comMay 22